Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNG462 in Combination Therapies for MTAP-Deleted Pancreatic and Non-Small Cell Lung Cancer
NCT06922591Phase 2Recruiting
- Sponsor
- Tango Therapeutics
- Start
- May 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vopimetostat in pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), sponsored by Tango Therapeutics. Started May 2025; status: recruiting.
02
Drugs
vopimetostat
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06922591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06922591.